

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization

WHO Technical Report Series

867

THE USE OF ESSENTIAL DRUGS

Seventh report of the
WHO Expert Committee

(including the revised Model List of Essential Drugs)



World Health Organization

Geneva 1997

WHO Library Cataloguing in Publication Data

WHO Expert Committee on the Use of Essential Drugs (1995 : Geneva, Switzerland)
The use of essential drugs : seventh report of the WHO expert committee

(WHO technical report series ; 867)

1.Essential drugs 2 Drug utilization 3.Guidelines I.Title II.Series

ISBN 92 4 120867 8

(NLM Classification: QV 55)

ISSN 0512-3054

The World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. Applications and enquiries should be addressed to the Office of Publications, World Health Organization, Geneva, Switzerland, which will be glad to provide the latest information on any changes made to the text, plans for new editions, and reprints and translations already available.

© World Health Organization 1997

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

**Typeset in Hong Kong
Printed in Spain**

96/11174 - Best-set/Fotojæ - 9300

Contents

1. Introduction	1
2. Guidelines for establishing a national programme for essential drugs	3
3. Criteria for the selection of essential drugs	5
4. Guidelines for the selection of pharmaceutical dosage forms	6
5. Quality assurance	7
5.1 WHO's Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce	8
5.2 Bioavailability	9
5.3 <i>The international pharmacopoeia</i>	9
5.4 Counterfeit drugs	10
6. Reserve anti-infective agents and monitoring of resistance	10
6.1 Need for surveillance of resistance	10
6.2 Reserve antimicrobials	11
7. Antiviral drugs	13
8. Applications of the essential drugs concept	13
9. Essential drugs and primary health care	14
9.1 Existing systems of medicine	14
9.2 The national health infrastructure	15
9.3 The pattern of endemic disease	15
9.4 Supplies	15
9.5 Medicinal drug promotion	15
10. Drug donations	15
11. Post-registration drug studies	16
12. Research and development	18
12.1 Pharmaceutical aspects	18
12.2 Clinical and epidemiological aspects	18
12.3 Educational aspects	19
13. Nomenclature	19
14. Drug information and educational activities	20
15. Updating of lists of essential drugs	23
16. Model List of Essential Drugs (ninth list)	23

17. Considerations and changes made in revising the model list	53
18. Glossary of terms used in the report	64
19. Alphabetical list of essential drugs	66
Acknowledgement	70
References	70
Annex 1	
Application form for inclusion in the Model List of Essential Drugs	74

WHO Expert Committee on the Use of Essential Drugs

Geneva, 4–8 December 1995

Members

Professor H. Fraser, Professor of Medicine and Clinical Pharmacology, Faculty of Medical Sciences, Queen Elizabeth Hospital, University of the West Indies, Bridgetown, Barbados (*Rapporteur*)

Dr A. Haeri, Dean, School of Medicine, Shaheed Beheshti University of Medical Sciences, Eeven, Teheran, Islamic Republic of Iran

Professor M. Hassar, Professor of Clinical Pharmacology, Department of Pharmacology, Faculty of Medicine and Pharmacy, University of Rabat, Rabat, Morocco (*Chairman*)

Dr G.P. Kilonzo, Senior Lecturer, Department of Psychiatry, Muhimbili Medical Centre, Dar-es-Salaam, United Republic of Tanzania

Ms A. Lim, Director, Drug Administration Division, Ministry of Health, Singapore

Professor L. Rago, Director-General, State Agency of Medicines, Tartu, Estonia

Professor M.M. Reidenberg, Chief, Division of Clinical Pharmacology, Cornell Medical Center, New York Hospital, New York, NY, USA

Professor L.A. Salako, Director-General, National Institute for Medical Research, Federal Ministry of Health and Social Services, Yaba, Lagos, Nigeria

Dr B. Santosa, Chairman, Faculty of Medicine, Department of Clinical Pharmacology, Gadjah Mada University, Yogyakarta, Indonesia (*Vice-Chairman*)

Professor M. Thomas, Head, Clinical Pharmacology and Adverse Drug Reactions Monitoring Centre, Christian Medical College and Hospital, Vellore, India

Representatives of other organizations*

International Federation of Pharmaceutical Manufacturers Associations (IFPMA)

Dr P. Appenzeller, IFPMA, Geneva, Switzerland

International League of Dermatological Societies

Professor J.-H. Saurat, Dermatology Clinic, Cantonal Hospital, University of Geneva, Geneva, Switzerland

International Pharmaceutical Federation (FIP)

Professor F.W.H.M. Merkus, Professor of Biopharmaceutics, University of Leiden, Leiden, Netherlands

International Society of Chemotherapy (ISC)

Professor T. Bergan, Department of Medical Microbiology, Institute of Medical Microbiology, National Hospital, Oslo, Norway

Professor J.D. Williams, Department of Medical Microbiology, London Hospital Medical College, London, England

* Unable to attend: Commonwealth Pharmaceutical Association (CPA); United Nations Industrial Development Organization (UNIDO).

International Union of Pharmacology (IUPHAR)

Professor J.P. Giroud, Head, Department of Pharmacology, Faculty of Medicine,
René-Descartes University, Academy of Paris, Paris, France

United Nations Children's Fund (UNICEF)

Ms H.B. Pedersen, Essential Drugs Unit, UNICEF, New York, NY, USA

World Federation of Proprietary Medicine Manufacturers (WFPMM)

Dr J.A. Reinstein, Director-General, WFPMM, London, England

Secretariat

Dr M.R. Couper, Medical Officer, Division of Drug Management and Policies,
WHO, Geneva, Switzerland (*Secretary*)

Dr J. Idänpään-Heikkilä, Director, Division of Drug Management and Policies,
WHO, Geneva, Switzerland

Professor N.A. Terragno, Professor of Clinical Pharmacology, University of Buenos
Aires, Buenos Aires, Argentina (*Temporary Adviser*)

Dr T. Tsukada, Professor, Health Centre (Hoken Centre), Chuo University, Tokyo,
Japan (*Temporary Adviser*)

1. Introduction

The WHO Expert Committee on the Use of Essential Drugs met in Geneva from 4 to 8 December 1995. The meeting was opened on behalf of the Director-General by Dr F.S. Antezana, Assistant Director-General, who emphasized that the concept of essential drugs was fundamental both to WHO's revised drug strategy (1), as endorsed by the World Health Assembly in resolution WHA39.27 in 1986 (2), and to the development of comprehensive national drug policies. Regular updating of WHO's Model List of Essential Drugs sustained the momentum of the revised drug strategy and was a basic element of the validated information required by most of WHO's Member States for optimal rationalization of drug procurement and supply. Dr Antezana also emphasized the importance of the emergence of resistance to antimicrobials that, in many cases, is dangerously eroding their effectiveness. This is leading to a situation whereby it will be increasingly difficult to combat serious infections. He requested the Committee to explore mechanisms whereby WHO could maintain a leadership role in this area in countries where the concept of having reserve antimicrobials runs counter to commercial interests.

The Committee decided to prepare its report as a self-contained document and to incorporate into it those parts of the previous report (3) that required no modification or merely bringing up to date. The ninth Model List of Essential Drugs will be found in section 16 of this report, and explanations of the changes in section 17.

In a report (4) to the Twenty-eighth World Health Assembly in 1975, the Director-General reviewed the main drug problems facing the developing countries and outlined possible new drug policies. The Director-General also referred to the experience gained in some countries where schemes of basic or essential drugs had been implemented. Such schemes were intended to extend the accessibility and rational use of the most necessary drugs to populations whose basic health needs could not be met by the existing supply system. The Director-General pointed out that the selection of these essential drugs would depend on the health needs and on the structure and development of the health services of each country. Lists of essential drugs should be drawn up locally, and periodically updated, with the advice of experts in public health, medicine, pharmacology, pharmacy and drug management. He also considered that adequate information on the properties, indications and use of the drugs listed should be provided. By resolution WHA28.66 (5), the Health Assembly requested the Director-General to implement the proposals contained in his report and, in particular, to advise Member States on

the selection and procurement, at reasonable cost, of essential drugs of established quality corresponding to their national health needs.

Following wide consultation, an initial Model List of Essential Drugs was included in the first report of the Expert Committee on the Selection of Essential Drugs (6). This has subsequently been revised and updated in seven further reports (3, 7-12).

In undertaking a further review of the list at its present meeting, the Expert Committee was guided throughout by the following statement contained in the previous reports:

Because of the great differences between countries, the preparation of a drug list of uniform, general applicability is not feasible or possible. Therefore, each country has the direct responsibility of evaluating and adopting a list of essential drugs, according to its own policy in the field of health.

The list of essential drugs based on the guidelines put forward in this report is a model which can furnish a basis for countries to identify their own priorities and to make their own selection.

The Committee also drew attention to the following guidelines set out in the initial report:

1. The extent to which countries implement schemes or establish lists of essential drugs is a national policy decision of each country.
2. As far as health services in developing countries are concerned, the organized procurement and use of essential drugs have many advantages in terms of economy and effectiveness. However, the concept of "essential drug lists" must accommodate a variety of local situations if the lists are ever to meet the real health needs of the majority of the population.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_30558

